Education
About Us
Working with TipRanks
Follow Us
Atara Biotherapeutics (GB:0HIY)
LSE:0HIY
RESEARCH TOOLSreports
0HIY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.44 - $20.77
Previous CloseN/A
Volume370.00
Average Volume (3M)3.02K
Market Cap
$36.09M
Enterprise Value$81.44M
Total Cash (Recent Filing)$60.70M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.50
Next Earnings
May 07, 2025EPS Estimate
-2.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.87
Shares Outstanding5,858,909
10 Day Avg. Volume1,329
30 Day Avg. Volume3,019
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.40
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap2.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.75
Enterprise Value/Ebitda-0.66
Forecast
1Y Price Target
$9.67Price Target Upside57.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Atara Biotherapeutics News
See All GB:0HIY News
---
Bulls Say, Bears Say
Bulls Say
Funding And Financial SupportAtara received a $15M equity line of credit from Redmile group, which should fund Ebvallo into BLA resubmission.
Potential Future MilestonesAtara could receive a $60M milestone in early 2025, assuming US FDA tab-cel approval, extending Atara's cash runway for key data readouts in autoimmune and NHL.
Bears Say
Regulatory ChallengesEbvallo's BLA for EBV+ PTLD received a CRL/clinical hold due to issues at a 3rd party manufacturing facility.
---
Options Prices
Currently, No data available
---
Ownership Overview
34.11% Insiders
7.35% Mutual Funds
21.94% Other Institutional Investors
33.35% Public Companies and Individual Investors
0HIY FAQ
What was Atara Biotherapeutics’s price range in the past 12 months?
Atara Biotherapeutics lowest share price was $5.44 and its highest was $20.77 in the past 12 months.
What is Atara Biotherapeutics’s market cap?
Atara Biotherapeutics’s market cap is $36.09M.
When is Atara Biotherapeutics’s upcoming earnings report date?
Atara Biotherapeutics’s upcoming earnings report date is May 07, 2025 which is in 56 days.
How were Atara Biotherapeutics’s earnings last quarter?
Atara Biotherapeutics released its earnings results on Nov 12, 2024. The company reported -$2.93 earnings per share for the quarter, missing the consensus estimate of -$1.888 by -$1.042.
Is Atara Biotherapeutics overvalued?
According to Wall Street analysts Atara Biotherapeutics’s price is currently Undervalued.
Does Atara Biotherapeutics pay dividends?
Atara Biotherapeutics does not currently pay dividends.
What is Atara Biotherapeutics’s EPS estimate?
Atara Biotherapeutics’s EPS estimate is -2.56.
How many shares outstanding does Atara Biotherapeutics have?
Atara Biotherapeutics has 5,858,909 shares outstanding.
What happened to Atara Biotherapeutics’s price movement after its last earnings report?
Atara Biotherapeutics reported an EPS of -$2.93 in its last earnings report, missing expectations of -$1.888. Following the earnings report the stock price went up 2.024%.
Which hedge fund is a major shareholder of Atara Biotherapeutics?
Currently, no hedge funds are holding shares in GB:0HIY
---
Atara Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.67 (57.49% Upside)
$9.67 (57.49% Upside)
Blogger Sentiment
Bullish
GB:0HIY Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $31.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.64%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-34.08%
Trailing 12-Months
Company Description
Atara Biotherapeutics
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
---
0HIY Stock 12 Month Forecast
Average Price Target
$9.67
▲(57.49% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Cara Therapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering 0HIY
1 Year
1 Year Success Rate
16/41 ratings generated profit
1 Year Average Return
-3.50%
reiterated a buy rating 2 days ago
Copying John Newman's trades and holding each position for 1 Year would result in 39.02% of your transactions generating a profit, with an average return of -3.50% per trade.
---